

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

**Defective images within this document are accurate representations of the original documents submitted by the applicant.**

**Defects in the images may include (but are not limited to):**


- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORLED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

FIGURE 1

1 2 3 4 5 6 7 8



$\beta$ -actin

FIGURE 2





FIGURE 3



**FIGURE 4**




FIGURE 5A

1 2 3 4 5






FIGURE 5B

1 2 3 4 5



**FIGURE 6**



# FIGURE 7


Leader -----			
RAT	ATGGGCAGTCCGGTATTGAGGAGACCTTTCTGCCATCTGTCCACCTACAGCCTGCTCTGGGCCATAG	67	
MOU	-----T-----C-----A-T---G-----	67	
HUM	--GA-----TG---C---CT-----T-----G-T---T---G-	55	
V-like domain -----			
RAT	CAGCAGTAGCGCTGAGCACAGCTCAAGTGGAAGTGGTGACCCAGGATGAAAGAAAGCTGCTGCACAC	134	
MOU	-----GC-----	134	
HUM	-----G-T---T-----A-----C-----A---T---	122	
RAT	AACTGCATCCTTACGCTGTTCTCTAAAAACAACCCAGGAACCCCTGATTGTGACATGGCAGAAAAAG	201	
MOU	-----A-----T-----	201	
HUM	-----T-----AAA-C---GC---ATG-----G---C-C-----	189	
RAT	AAAGCCGTAGGCCCCAGAAAACATGGTCACTTACAGCAAAGCCCATGGGGTTGTCATTACAGCCACCT	268	
MOU	-----GA-----C-----A-----A---C---TG---	268	
HUM	-----T---A-----C-T---G-GAA-----G---G---C---TG---	256	
RAT	ACAAAGACAGGATAAACATCACTGAGCTGGGACTCTTGAACACAAGCATCACCTTCTGGAACACAAC	335	
MOU	-----TG---A-----G---T-----CA	335	
HUM	-T---G---A-----T---CC-----C-A---T---C-----T-TC--	323	
RAT	CCTGGATGATGAGGGTTGCTACATGTGTCTCTTCAACATGTTTGGATCTGGGAAGGTCTCTGGGACA	402	
MOU	-A-T-GA---GA---C-----C-----T---CA-----A---A---	402	
HUM	-----G-----A---G---T-----T-CC-----T-T-----A---A---G	390	
C-like domain -----			
RAT	GCTTGCCCTACTCTCTATGTACAGCCCATAGTACACCTTCACTACAACCTATTTTGAAGACCACCTAA	469	
MOU	-----C-----	469	
HUM	--C-----C---CG-----TC-----A-TC-C-----	457	
RAT	ACATCACGTGCTCTGCAACTGCCCGCCAGCCCTGCCATCTCCTGGAAGGGCACTGGGTGAGGAAT	536	
MOU	-----T-----G-----T-----A-----T-----A-----	536	
HUM	-T-----T-----C-----CATGG---T-----T-C-C-----	524	
RAT	TGAGAATAGTACTGAGAGTCACTCCCATTCAAATGGGACTACATCTGTCACCAGCATCCTCCGGGTC	603	
MOU	-----C-----T-----	603	
HUM	---A-----A-T---C---TG---T---CC-----C---G-----T-----ATA--	591	
RAT	AAAGACCCCAAACTCAGGTTGGAAAGGAAGTGATCTGCCAGGTTTATACTTGGGGAATGTGATTG	670	
MOU	-----	670	
HUM	-----T---G-A-----G---G-----GC-GC---C-----C---CC-	658	
Transmembrane region -----			
RAT	ACTACAAGCAGAGTCTGGACAAAGGATTTTGGTTTTTCAGTCCCACTGCTGCTGAGCATTGTTTCTCT	737	
MOU	-----T-----T-----A-----	737	
HUM	---TT-----A-CCG-CA-----C-A-----T---G---AT---A-----C---	725	
Cytoplasmic region -----			
RAT	GGTAATTCTTCTGGTCTTGATCTCCATCTTATTATACTGGAAACGGCACCAGAAATCAGGAGCGGGGT	804	
MOU	-----A-----C-----T-----	804	
HUM	-----C---C-A---A---C-G-----T---G-----C---A---	792	
RAT	GAGTCATCACAGGGGATGCAAAGAATGAAATAA	837	
MOU	---A-----	837	
HUM	----TG-----AG-T---A-----C----	825	



[illegible]


\* invariant cysteine residues; \*\* invariant asparagine (N-linked oligosaccharides)

**FIGURE 9**




CELLS added to C57BL/6 RESPONDER SPLEEN CELLS

**FIGURE 10**




**FIGURE 11**




**NPC from Flt3 treated mice**


**FIGURE 12**



**FIGURE 13**




**FIGURE 14**



NPC cells infused into renal transplant recipients

**FIGURE 15**





**FIGURE 16**






FIGURE 18A





FIGURE 18B



FO0E70" 8224T660

# Survival post EL4 or C1498 tumor inoculation in C57BL/6 bone marrow transplant recipients





FIGURE 19

Increased survival after EL4 tumor  
inoculation in C57BL/6 mice immunized  
with CD80 transfected EL4 cells




FIGURE 20

# Role of CD4<sup>+</sup>/CD8<sup>+</sup> cells in tumor immunity in bone marrow transplant recipients




FIGURE 21

# CD200Fc reverses tumor protection in C3H recipients of C57BL/6 bone marrow





FIGURE 22

**CD200Fc reverses protection from early mortality in C57BL/6 mice immunized with CD80-transfected EL4 cells**



**FIGURE 23**



# Anti-CD200 reveals protection in mice preimmunized with CD86-tumor cells






FIGURE 24

**Relative CD200 mRNA expression in spleen following immunization with EL4-CD86 vs EL4-CD80**



**Cells used for immunization of C57BL/6**

**FIGURE 25**

# CD200:CD200<sup>r+</sup> interactions block tumor immunity in BL/6 marrow recipients





FIGURE 26

# CD200Fc interacts with anti-CD4/CD8 to block tumor immunity

a)



b)




FIGURE 27

# CD200Fc reverses protection from early mortality in anti-CD4 treated C57BL/6 mice immunized with CD80-transfected EL4 cells





FIGURE 28


FIGURE 29A and B



A

B


**FIGURE 30A and B**



A

B

FIGURE 31A and B



A

B